X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The funding will be used to support the Phase III clinical development of dexpramipexole. It is an eosinophil maturation inhibitor that will be used in the treatment of Eosinophilic Asthma.
Lead Product(s): Dexpramipexole
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: KNS-760704
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Viking Global Investors
Deal Size: $425.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing February 13, 2024
Details:
Dexpramipexole dihydrochloride inhibits the maturation and release of eosinophils in bone marrow, based on evidence from cell cultures and human biopsies, thereby lowering peripheral blood eosinophil levels. It is being developed for moderate-to-severe eosinophilic asthma.
Lead Product(s): Dexpramipexole
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 09, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
